DEVELOPING HIGH POTENCY AND LOW TOXICITY TARGETED THERAPEUTICS
Xcovery is a biopharmaceutical company with the aim to improve the lives of cancer patients by discovering and developing innovative medicines to fight advanced tumors. We are working on a pipeline of oncology therapies to target a wide range of malignant diseases.
Our lead product, ensartinib (X-396), is a small molecule that inhibits anaplastic lymphoma kinase (ALK). Ensartinib is being investigated for the treatment of ALK positive non-small cell lung cancer. We recently concluded enrollment for the Phase 3 study. Please consult with your oncologist for questions about our studies.
NEWS
Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC
Check out our recent article posted on OncLive highlighting the promising activity observed with our investigational ensartinib agent! https://lnkd.in/eMTwb-i
IASLC 18th World Conference on Lung Cancer, Yokohama, Japan
Xcovery is presenting a poster entitled:
eXalt3: First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study
Yi-Long Wu, Tony S. Mok, Martin Reck, Heather A. Wakelee, Chris Liang, Fenlai Tan, Kimberly Harrow, Vance Oertel, Gary Dukart, Lieming Ding, Leora Horn
The overall study objective is to evaluate the efficacy and safety of ensartinib vs crizotinib in patients with ALK+ NCSLC that have received up to 1 prior chemotherapy regimen and no prior ALK TKI. Ensartinib exhibited favorable effectiveness in in vitro and in vivo studies, including mutations that are resistant or become resistant to crizotinib. The eXalt3 trial was initiated in June 2016 and over 42 sites have been activated. Xcovery is presenting updated preliminary data on the efficacy and safety of ensartinib.
IASLC 18th World Conference on Lung Cancer, Yokohama, Japan
Xcovery is presenting a mini-oral presentation entitled:
Response to Ensartinib in TKI naïve ALK+ NSCLC patients
Heather A. Wakelee, Rachel E. Sanborn, Jorge Nieva, Saiama Naheed Waqar, Christina E. Brzezniak, Jessica Bauman, Joel W. Neal, Gary Dukart, Fenlai Tan, Kimberly Harrow, Chris Liang, Leora Horn
Ensartinib has shown clinical activity in patients harboring an ALK alteration including EML4-ALK fusion or point mutation such as T1151M, G1269A, L1196M, G1202R and V1149M. Xcovery is presenting preliminary results from the ongoing eXalt2 phase 2 study. Overall response rates in the ALK TKI naïve sub-population are 92% in NGS confirmed ALK+ subjects.
Durable responses and clinically meaningful intracranial responses were observed. Ensartinib is generally well tolerated with the most common AE, rash, being easily treated. Responses are also seen in patients treated with at least one 2nd generation ALK TKI and in patients with prior crizotinib. The eXalt3, a phase III trial, is ongoing, comparing ensartinib to crizotinib in TKI naïve ALK-positive NSCLC patients.
EVENTS
American Society of Clinical Oncology (ASCO) in Chicago, Illinois – June 1-5, 2018
The Xcovery team will be attending American Society of Clinical Oncology (ASCO) in Chicago, Illinois on June 1-5, 2018. Please email Olivia@xcovery.com if you would like to schedule time to meet with the team. We hope to see you there!
European Lung Cancer Congress (ELCC) in Geneva, Switzerland – April 11-14, 2018
The Xcovery team will be attending European Lung Cancer Congress (ELCC) on April 11-14, 2018 in Geneva, Switzerland.
OUR VISION & CULTURE
Xcovery is committed to bettering lives by providing superior therapies for cancer patients. Founded in 2006 with a passion of bringing humanity back to cancer treatment, Xcovery set out to improve existing effective treatments.
We not only want to bring that compassion and human touch to our patients, but to our team, our partners and treating physicians.
OUR LEADERSHIP
Lieming Ding, M.D, Chairman of the Board
Lieming Ding, M.D., serves as Chairman of the Board at Xcovery. Dr. Ding currently is also the chairman and CEO of Betta Pharmaceuticals Co., Ltd. He returned to China from US in 2002 to start Betta Pharmaceuticals Co., Ltd, a company focusing on research and development of innovative drugs. In August 2011, Betta Pharmaceutical launched icotinib (Conmana), the first targeted therapy developed in China for non-small cell lung cancer, which is a milestone for the Chinese anticancer industry. In 2012 and 2014, the WIPO and SIPO of China issued Gold award to icotinib for its two invention patents. Icotinib won the first prize of the National Science and Technology Progress Award in 2016, which is the first time that the chemical and pharmaceutical industry won the prize. In the same year, icotinib also won the China Industry Award, the top accolade of industry sector. To date, icotinib has a total sales revenue of over 3.4 billion RMB and has benefited more than 100,000 patients. Dr. Ding’s accomplishment in Chinese pharmaceutical industry has won him numerous honors, such as distinguished expert of All-China Federation of Returned Overseas Chinese, Deputy of the 12th National Peoples’ Congress, key member of Chinese National Key Special Program of Innovative Drugs, and Chairman of China Pharmaceutical Innovation and Research Development Association (PhIRDA).
Dr. Ding completed his resident training in pathology at University of Arkansas for Medical Sciences.
Chris Liang, Ph.D., EVP and Chief Scientific Officer
Chris Liang, Ph.D., is the co-founder of Xcovery. He is a leading scientist in the design of protein kinase inhibitors who has authored more than 40 scientific publications and secured more than 50 patents. Dr. Liang is co-developer of Sutent®, an FDA approved multi-kinase inhibitor for resistant gastrointestinal stromal tumors, advanced renal cell carcinoma, and advanced, progressive, well-differentiated pancreatic neuroendocrine tumors, which he developed while serving as director of medicinal chemistry at SUGEN. SUGEN and Sutent® were acquired by Pfizer. Additionally, Dr. Liang served as director of medicinal chemistry at Scripps Research Institute in Florida before starting Xcovery.
Dr. Liang’s research focuses on the design of protein kinase inhibitors by combining computational modeling, medicinal chemistry and broad knowledge in other areas of drug discovery. His recent work has focused on the reduction of toxicity in existing multi-kinase inhibitors. Dr. Liang holds a Ph.D. in theoretical chemistry from Princeton University.
Kimberly Harrow, MBA, Vice President, Clinical Operations
Kimberly Harrow has been with Xcovery since its founding and has more than 15 years of oncology research and development experience. Ms. Harrow manages the worldwide clinical operations for all of Xcovery’s development programs, including clinical trials. Ms. Harrow holds an MBA and B.S. in biology from the University of Florida.
Cristina Mallory, MS., & MBA, Vice President, Finance & Administration
Cristina Mallory joined Xcovery in 2016 and brought with her a solid background in Finance and Accounting; having spent over 15 years at Thermo Fisher Scientific in various finance leadership role. Ms. Mallory manages the global process within finance and accounting, including business administration, compliance and human resources. Ms. Mallory holds an MBA from the University of Florida, M.S. and B.S. in Business Administration, major in Accounting from the University of St Thomas.
Strategic Partners
Partnering Drives Innovation
Xcovery has partnered with Betta Pharmaceuticals for the development of ensartinib in China. Betta is also the majority shareholder of Xcovery. The development of X-379 (MET inhibitor) in China is partnered with Anew Pharma.
JOIN US
Welcome to Xcovery. Welcome to Opportunity.
At Xcovery, we value talent, one of the cornerstones of our success. Our aim is to discover, recruit and retain a staff of exceptional people to maintain our position as an industry leader. Our focus on our employees, whether working at the office or at a remote location, ensures we are operating as one team; it’s our sense of team spirit that truly defines the Xcovery culture.
Our commitment to our employees as well as our employees’ engagement is what enables us to do what we love – to promote and advance science. If you are interested in joining our team, we invite you to apply today. Please email your resume and cover letter to humanresources@xcovery.com. We are proud to be an equal opportunity employer. All applicants must be legally authorized to work in the U.S.
CONTACT US